Market was valued at USD 1564 Million in 2023 and is anticipated to reach USD 5374 Million by 2030, witnessing a CAGR of 16.9% during the forecast period 2024-2030.

Baseline fracture risk for prostate cancer patients initiating long-term androgen deprivation therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...

Real-world data support trial data on the use of lutetium-177 PSMA-617 in patients with PSMA-positive, metastatic castration-resistant prostate cancer.

Using an ARPI or taxane after 177Lu-PSMA-617 can produce a robust PSA response in patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu-PSMA-617) was approved in 2022 for patients with metastatic ...

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

Characterization of circulating tumor DNA (ctDNA) burden and its association with real-world overall survival among prostate cancer (PC) patients. Cancer-control outcomes of metastatic castration ...

Safety profile of lutetium-177 in patients with impaired renal function: A retrospective analysis of adverse events in mCRPC treatment. Dr. Saylani highlighted that Lutetium-177 vipivotide tetraxetan ...

It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify patients for whom PSMA-targeted therapy with (177 Lu)lutetium vipivotide ...

PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. The New England Journal of Medicine, 385(12), 1091–1103.